In the near future we hope to see clinical imaging with Aβ ligands combined with assessments of other recently identified AD risk genes (up to and including IHC for their protein products at autopsy) such as for specific variants of clusterin (CLU, Apo J), complement component receptor 1 (CR1), phosphatidylinositol binding clathrin assembly protein (PICALM) [61], until a more powerful algorithm is achieved that will almost certainly inform the identity of one or more useful drug targets (drugs) for the slowing, prevention, and/or arrest of this ultimately devastating pathology. The gene discussed is CLU; the disease is Alzheimer disease.